Aligos Therapeutics Inc - ESG Rating & Company Profile powered by AI
This report of Aligos Therapeutics Inc employs data from across the web and also from public filings by Aligos Therapeutics Inc. Check the end of this page for potential risks for Aligos Therapeutics Inc based on sector, location and size. If you work at Aligos Therapeutics Inc and you would like to licence your Sustainability rating, please get in touch.
Aligos Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.6; made up of an environmental score of 4.0, social score of 6.4 and governance score of 6.4.
5.6
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 579 | Tonix Pharmaceuticals Holding Corp | 5.7 | High |
| 579 | VIVA Biotech Holdings | 5.7 | High |
| 602 | Aligos Therapeutics Inc | 5.6 | High |
| 602 | Celltrion Inc | 5.6 | High |
| 602 | Adaptimmune Therapeutics PLC | 5.6 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Aligos Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Aligos Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Aligos Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Aligos Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Aligos Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Aligos Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Aligos Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Aligos Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Aligos Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Aligos Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Aligos Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Aligos Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Aligos Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Aligos Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Aligos Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Aligos Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Aligos Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Aligos Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-ß agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting SARS-CoV-2; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It has research partnership with Vipergen ApS to develop DNA Encoded Library (DEL)-based drug discovery for viral infections and liver diseases. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.